Robert L Coleman Selected Research

Poly(ADP-ribose) Polymerase Inhibitors

1/2024	Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor.
11/2023	Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032).
5/2023	The evolving landscape of antibody-drug conjugates in gynecologic cancers.
1/2023	Systemic therapy de-escalation in advanced ovarian cancer: a new era on the horizon?
1/2023	Response to letter to the editor "AML and MDS associated with PARP inhibitor treatment of ovarian cancer".
12/2022	Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.
3/2022	Feasibility Study of a Network Meta-Analysis and Unanchored Population-Adjusted Indirect Treatment Comparison of Niraparib, Olaparib, and Bevacizumab as Maintenance Therapies in Patients with Newly Diagnosed Advanced Ovarian Cancer.
1/2022	Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
12/2021	Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models.
12/2021	Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Robert L Coleman Research Topics

Disease

185	Ovarian Neoplasms (Ovarian Cancer) 01/2024 - 01/2002
179	Neoplasms (Cancer) 04/2024 - 01/2002
70	Carcinoma (Carcinomatosis) 04/2024 - 01/2002
42	Endometrial Neoplasms (Endometrial Cancer) 04/2024 - 01/2007
42	Ovarian Epithelial Carcinoma 01/2023 - 01/2002
24	Disease Progression 01/2024 - 07/2008
24	Uterine Cervical Neoplasms (Cancer of the Cervix) 05/2023 - 02/2002
11	Neoplasm Metastasis (Metastasis) 01/2021 - 12/2006
10	Neutropenia 01/2023 - 04/2006
8	Nausea 04/2024 - 01/2008
8	Uterine Neoplasms (Uterine Cancer) 05/2023 - 05/2009
8	Fatigue 01/2023 - 01/2008
8	Adenocarcinoma 01/2022 - 03/2004
8	Fallopian Tube Neoplasms 12/2021 - 12/2006
7	Anemia 12/2022 - 11/2015
6	Breast Neoplasms (Breast Cancer) 01/2023 - 03/2009
6	Hypertension (High Blood Pressure) 01/2022 - 11/2011
6	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2020 - 03/2002
5	Hypoxia (Hypoxemia) 02/2018 - 11/2011
4	Vomiting 04/2024 - 01/2008
4	Thrombocytopenia (Thrombopenia) 01/2023 - 05/2011
4	Sarcoma (Soft Tissue Sarcoma) 01/2021 - 01/2020
4	Vulvar Neoplasms (Vulvar Cancer) 04/2020 - 11/2012
4	Ascites 10/2016 - 01/2011
3	Exanthema (Rash) 01/2022 - 04/2006
3	Granulosa Cell Tumor 04/2020 - 09/2009

Drug/Important Bio-Agent (IBA)

84	PlatinumIBA 04/2024 - 01/2002
40	Paclitaxel (Taxol)FDA LinkGeneric 01/2023 - 01/2002
38	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2024 - 06/2015
31	Biomarkers (Surrogate Marker)IBA 04/2024 - 03/2004
29	Bevacizumab (Avastin)FDA Link 11/2023 - 12/2007
26	Carboplatin (JM8)FDA LinkGeneric 01/2023 - 01/2002
24	rucaparibIBA 01/2023 - 06/2016
22	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 08/2006
17	taxaneIBA 11/2017 - 01/2002
16	Docetaxel (Taxotere)FDA Link 01/2016 - 08/2006
15	liposomal doxorubicin (Doxil)FDA Link 01/2023 - 08/2004
13	Proteins (Proteins, Gene)FDA Link 04/2024 - 07/2008
13	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 03/2022 - 07/2013
13	Topotecan (Hycamtin)FDA LinkGeneric 11/2020 - 01/2002
12	Small Interfering RNA (siRNA)IBA 01/2022 - 08/2006
11	Immunoconjugates (Immunoconjugate)IBA 05/2023 - 09/2009
10	olaparibIBA 03/2022 - 11/2018
9	Monoclonal AntibodiesIBA 01/2023 - 09/2009
8	1-dodecylpyridoxal (PLD)IBA 11/2021 - 10/2006
7	niraparibIBA 11/2023 - 11/2018
7	Poly Adenosine Diphosphate RiboseIBA 01/2023 - 01/2020
7	veliparibIBA 01/2023 - 06/2015
7	Progesterone Receptors (Progesterone Receptor)IBA 04/2020 - 06/2009
7	Cisplatin (Platino)FDA LinkGeneric 01/2020 - 01/2002
6	pembrolizumabIBA 04/2024 - 01/2018
6	AntigensIBA 12/2023 - 07/2016
6	tisotumab vedotinIBA 05/2023 - 01/2020
6	farletuzumabIBA 01/2023 - 03/2010
6	Folic Acid (Vitamin M)FDA LinkGeneric 01/2023 - 06/2013
6	Folate Receptor 1IBA 01/2023 - 03/2010
6	Estrogen ReceptorsIBA 11/2020 - 07/2008
5	selinexorIBA 04/2024 - 12/2021
5	mirvetuximab soravtansineIBA 12/2023 - 03/2015
5	dostarlimabIBA 11/2023 - 12/2022
5	FANG vaccineIBA 02/2023 - 12/2020
5	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2022 - 07/2015
5	trametinibIBA 01/2022 - 01/2015
5	Letrozole (Femara)FDA LinkGeneric 01/2022 - 07/2008
5	Everolimus FDA Link 01/2022 - 12/2010
5	ErbB Receptors (EGF Receptor)IBA 11/2020 - 01/2007
5	Angiogenesis InhibitorsIBA 10/2020 - 12/2009
5	Taxoids (Taxanes)IBA 01/2020 - 08/2006
5	Focal Adhesion Protein-Tyrosine KinasesIBA 05/2019 - 08/2006
5	Gemcitabine FDA Link 01/2017 - 03/2007
5	afliberceptIBA 01/2016 - 04/2008
5	LigandsIBA 01/2016 - 02/2007
5	Proliferating Cell Nuclear Antigen (PCNA)IBA 11/2011 - 09/2006
5	1,2-oleoylphosphatidylcholine (DOPC)IBA 11/2011 - 08/2006
4	EC145IBA 01/2023 - 12/2013
4	Peptides (Polypeptides)IBA 01/2021 - 04/2014
4	DNA (Deoxyribonucleic Acid)IBA 10/2020 - 12/2008
4	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 06/2016 - 01/2007
3	Thromboplastin (Tissue Factor)IBA 01/2023 - 01/2020
3	MK 2206IBA 04/2022 - 01/2020
3	Dasatinib (BMS 354825)FDA Link 10/2021 - 04/2014
3	TrabectedinIBA 01/2021 - 01/2020
3	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 01/2021 - 01/2014
3	Hemoglobins (Hemoglobin)IBA 01/2021 - 02/2013
3	Tyrosine Kinase InhibitorsIBA 11/2020 - 07/2014
3	Hormones (Hormone)IBA 04/2020 - 06/2009

Therapy/Procedure

158	Therapeutics 04/2024 - 01/2002
94	Drug Therapy (Chemotherapy) 01/2024 - 01/2002
15	Hysterectomy 12/2022 - 02/2002
13	Neoadjuvant Therapy 01/2022 - 03/2008
12	Immunotherapy 04/2024 - 01/2015
12	Lymph Node Excision (Lymph Node Dissection) 10/2021 - 02/2002
9	Cytoreduction Surgical Procedures 01/2023 - 10/2010
5	Radiotherapy 12/2022 - 01/2005
5	Salpingo-oophorectomy 12/2022 - 03/2009
5	Combination Drug Therapy (Combination Chemotherapy) 04/2011 - 03/2007
4	Laparotomy 01/2020 - 01/2007
4	Minimally Invasive Surgical Procedures 01/2020 - 10/2010
4	Drug Tapering 01/2019 - 04/2006
3	Aftercare (After-Treatment) 11/2020 - 01/2007